The role of toxin A and toxin B in the virulence of Clostridium difficile

Trends in Microbiology

Volumn 20, Issue 1, 2012, Pages 21-29

  Carter, Glen P ^a   Rood, Julian I ^a   Lyras, Dena ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; RHO GUANINE NUCLEOTIDE BINDING PROTEIN;

BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONFORMATIONAL TRANSITION; CYTOTOXICITY; ENDOCYTOSIS; GENE MAPPING; HUMAN; INTESTINE EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; RECEPTOR BINDING; REVIEW; TCDA GENE; TCDB GENE; TCDC GENE; TCDE GENE; TOXIN STRUCTURE;

BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROTOXINS; HUMANS; VIRULENCE; VIRULENCE FACTORS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM DIFFICILE;

EID: 84855510455     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2011.11.003     Document Type: Review

References (84)

1. Borriello S.P. Pathogenesis of Clostridium difficile infection. J. Antimicrob. Chemother. 1998, 41:13-19.
2. Kyne L. Clostridium difficile: beyond antibiotics. N. Engl. J. Med. 2010, 362:264-265.
3. Bartlett J.G. Antibiotic-associated diarrhea. N. Engl. J. Med. 2002, 346:334-339.
4. McDonald L.C., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. 2005, 353:2433-2441.
5. Warny M., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005, 366:1079-1084.
6. Freeman J., et al. The changing epidemiology of Clostridium difficile infections. Clin. Microbiol. Rev. 2010, 23:529-549.
7. Stabler R.A., et al. Comparative genome and phenotypic analysis of Clostridium difficile 027 strains provides insight into the evolution of a hypervirulent bacterium. Genome Biol. 2009, 10:R102.
8. Loo V.G., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005, 353:2442-2449.
9. Baker S.S., et al. Increasing incidence of community-associated atypical Clostridium difficile disease in children. Clin. Pediatr. (Phil.) 2010, 49:644-647.
10. Rouphael N.G., et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am. J. Obstet. Gynecol. 2008, 198:635e1-635e6.
11. Zilberberg M.D., et al. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg. Infect. Dis. 2010, 16:604-609.
12. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 2005, 18:247-263.
13. Perelle S., et al. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect. Immun. 1997, 65:1402-1407.
14. Schwan C., et al. Clostridium difficile toxin CDT induces formation of microtubule-based protrusions and increases adherence of bacteria. PLoS Pathog. 2009, 5:e1000626.
15. Goulding D., et al. Distinctive profiles of infection and pathology in hamsters infected with Clostridium difficile strains 630 and B1. Infect. Immun. 2009, 77:5478-5485.
16. Dawson L.F., et al. The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains. BMC Microbiol. 2011, 11:86.
17. Barketi-Klai A., et al. Role of fibronectin-binding protein A in Clostridium difficile intestinal colonization. J. Med. Microbiol. 2011, 60:1155-1161.
18. Janoir C., et al. Cwp84, a surface-associated protein of Clostridium difficile, is a cysteine protease with degrading activity on extracellular matrix proteins. J. Bacteriol. 2007, 189:7174-7180.
19. Kirby J.M., et al. Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J. Biol. Chem. 2009, 284:34666-34673.
20. Reynolds C.B., et al. The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog. 2011, 7:e1002024.
21. Calabi E., et al. Molecular characterization of the surface layer proteins from Clostridium difficile. Mol. Microbiol. 2001, 40:1187-1199.
22. Bianco M., et al. Immunomodulatory activities of surface-layer proteins obtained from epidemic and hypervirulent Clostridium difficile strains. J. Med. Microbiol. 2011, 60:1162-1167.
23. Dingle T.C., et al. Mutagenic analysis of the Clostridium difficile flagellar proteins, FliC and FliD, and their contribution to virulence in hamsters. Infect. Immun. 2011, 79:4061-4067.
24. Braun V., et al. Definition of the single integration site of the pathogenicity locus in Clostridium difficile. Gene 1996, 181:29-38.
25. Mani N., Dupuy B. Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:5844-5849.
26. Matamouros S., et al. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol. Microbiol. 2007, 64:1274-1288.
27. White R., et al. Holin triggering in real time. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:798-803.
28. Tan K.S., et al. Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J. Med. Microbiol. 2001, 50:613-619.
29. Pépin J., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. Dis. 2005, 41:1254-1260.
30. Redelings M.D., et al. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg. Infect. Dis. 2007, 13:1417-1419.
31. Riley T.V. Is Clostridium difficile a threat to Australia's biosecurity?. Med. J. Aust. 2009, 190:661-662.
32. O'Brien J.A., et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect. Cont. Hosp. Epidemiol. 2007, 28:1219-1227.
33. Merrigan M., et al. Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J. Bacteriol. 2010, 192:4904-4911.
34. Carter G.P., et al. The anti-sigma factor TcdC modulates hypervirulence in an epidemic BI/NAP1/027 clinical isolate of Clostridium difficile. PLoS Pathog. 2011, 7:e1002317.
35. Lanis J.M., et al. Variations in TcdB activity and the hypervirulence of emerging strains of Clostridium difficile. PLoS Pathog. 2010, 6.
36. Carter G.P., et al. Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J. Bacteriol. 2007, 189:7290-7301.
37. Geric B., et al. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J. Med. Microbiol. 2004, 53:887-894.
38. Rupnik M. Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease?. Eur. Soc. Clin. Microbiol. Infect. Dis. 2007, 13:457-459.
39. Schwan C., et al. Cholesterol- and sphingolipid-rich microdomains are essential for microtubule-based membrane protrusions induced by Clostridium difficile transferase CDT. J. Biol. Chem. 2011, 286:29356-29365.
40. Sebaihia M., et al. The multidrug-resistant human pathogen Clostridium difficile has a highly mobile, mosaic genome. Nat. Genet. 2006, 38:779-786.
41. Voth D.E., et al. Variations in lethal toxin and cholesterol-dependent cytolysin production correspond to differences in cytotoxicity among strains of Clostridium sordellii. FEMS Microbiol. Lett. 2006, 259:295-302.
42. Busch C., et al. Characterization of the catalytic domain of Clostridium novyi alpha-toxin. Infect. Immun. 2000, 68:6378-6383.
43. Amimoto K., et al. A novel toxin homologous to large clostridial cytotoxins found in culture supernatant of Clostridium perfringens type C. Microbiology 2007, 153:1198-1206.
44. Jank T., Aktories K. Structure and mode of action of clostridial glucosylating toxins: the ABCD model. Trends Microbiol. 2008, 16:222-229.
45. Genisyuerek S., et al. Structural determinants for membrane insertion, pore formation and translocation of Clostridium difficile toxin B. Mol. Microbiol. 2011, 79:1643-1654.
46. Qa'Dan M., et al. pH-induced conformational changes in Clostridium difficile toxin B. Infect. Immun. 2000, 68:2470-2474.
47. Pruitt R.N., et al. Structural organization of the functional domains of Clostridium difficile toxins A and B. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13467-13472.
48. Guttenberg G., et al. Inositol hexakisphosphate-dependent processing of Clostridium sordellii lethal toxin and Clostridium novyi alpha-toxin. J. Biol. Chem. 2011, 286:14779-14786.
49. Pothoulakis C., et al. Nerves and intestinal mast cells modulate responses to enterotoxins. News Physiol. Sci. 1998, 13:58-63.
50. Pothoulakis C. Effects of Clostridium difficile toxins on epithelial cell barrier. Ann. N. Y. Acad. Sci. 2000, 915:347-356.
51. Stabler R.A., et al. Comparative analysis of BI/NAP1/027 hypervirulent strains reveals novel toxin B-encoding gene (tcdB) sequences. J. Med. Microbiol. 2008, 57:771-775.
52. Rupnik M., et al. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J. Clin. Microbiol. 1998, 36:2240-2247.
53. Rupnik M. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol. Rev. 2008, 32:541-555.
54. Elliott B., et al. New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. J. Med. Microbiol. 2011, 60:1108-1111.
55. Drudy D., et al. Toxin A-negative, toxin B-positive Clostridium difficile. Int. J. Infect. Dis. 2007, 11:5-10.
56. Dingle K.E., et al. Clinical Clostridium difficile: clonality and pathogenicity locus diversity. PLoS ONE 2011, 6:e19993.
57. Lyerly D.M., et al. Effects of Clostridium difficile toxins given intragastrically to animals. Infect. Immun. 1985, 47:349-352.
58. Mitchell T.J., et al. Effect of toxin A and B of Clostridium difficile on rabbit ileum and colon. Gut 1986, 27:78-85.
59. Lima A.A.M., et al. Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro. Infect. Immun. 1988, 56:582-588.
60. Ketley J.M., et al. The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits. J. Med. Microbiol. 1987, 24:41-52.
61. Kim P.H., et al. Immunization of adult hamsters against Clostridium difficile-associated ileocecitis and transfer of protection to infant hamsters. Infect. Immun. 1987, 55:2984-2992.
62. Corthier G., et al. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect. Immun. 1991, 59:1192-1195.
63. Bacon A.E., Fekety R. Immunoglobulin G directed against toxins A and B of Clostridium difficile in the general population and patients with antibiotic-associated diarrhea. Diagn. Microbiol. Infect. Dis. 1994, 18:205-209.
64. Savidge T.C., et al. Clostridium difficile toxin B is an inflammatory enterotoxin in human intestine. Gastroenterology 2003, 125:413-420.
65. Hamm E.E., et al. Identification of Clostridium difficile toxin B cardiotoxicity using a zebrafish embryo model of intoxication. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:14176-14181.
66. Dobson G., et al. Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med. 2003, 29:1030.
67. Lyras D., et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-1179.
68. Kuehne S.A., et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-713.
69. Carter G.P., et al. The role of toxin A and toxin B in Clostridium difficile-associated disease: past and present perspectives. Gut Microbes 2010, 1:58-64.
70. Carter G.P., et al. TcdB or not TcdB: a tale of two Clostridium difficile toxins. Future Microbiol. 2011, 6:121-123.
71. Ballard J.D. Medical microbiology: a toxin contest. Nature 2010, 467:665-666.
72. Chen X., et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology 2008, 135:1984-1992.
73. Steele J., et al. Piglet models of acute or chronic Clostridium difficile illness. J. Infect. Dis. 2010, 201:428-434.
74. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int. J. Antimicrob. Agents 2009, 33:4-7.
75. Hundsberger T., et al. Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur. J. Biochem. 1997, 244:735-742.
76. Dunbar N.M., Harruff R.C. Necrotizing fasciitis: manifestations, microbiology and connection with black tar heroin. J. Forensic Sci. 2007, 52:920-923.
77. Aronoff D.M., et al. Misoprostol impairs female reproductive tract innate immunity against Clostridium sordellii. J. Immunol. 2008, 180:8222-8230.
78. Aldape M.J., et al. Clostridium sordellii infection: epidemiology, clinical findings, and current perspectives on diagnosis and treatment. Clin. Infect. Dis. 2006, 43:1436-1446.
79. Majumdar S., et al. Severe sepsis following wound infection by an unusual organism - Clostridium novyi. Int. J. Clin. Pract. 2004, 58:892-893.
80. McClane B. Clostridium perfringens type C isolates rapidly upregulate their toxin production upon contact with host cells: new insights into virulence?. Virulence 2010, 1:97-100.
81. Dang L.H., et al. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:15155-15160.
82. Carter G.P., et al. TcsL is an essential virulence factor in Clostridium sordellii ATCC 9714. Infect. Immun. 2011, 79:1025-1032.
83. Just I., Gerhard R. Large clostridial cytotoxins. Rev. Physiol. Biochem. Pharmacol. 2004, 152:23-47.
84. Bhattacharyya S., et al. Fluorescent analogs of UDP-glucose and their use in characterizing substrate binding by toxin A from Clostridium difficile. Eur. J. Biochem. 2002, 269:3425-3432.